Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$21.6M
15M shares
52-week range
$1.13 – $3.78
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
www.darebioscience.comNo one on the platform currently holds DARE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 10,195 | $18.6K |
| Execution date | Ratio |
|---|---|
| 2024-07-01 | 1-for-12reverse |
No one on the platform has traded DARE yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BAOS $ACXP $ONFO $CAST $DARE This one is back on my radar! 📈 I’m watching for a potential high-volatility bounce and looking for the right entry instead of chasing the spike. https://www.youtube.com/watch?v=EpAfFgljOJY
View on StockTwits ↗🌅 Watchlist part 1 ✅ $AKAN low 9 support, above 10, potential to 11/12 ✅ $CAPR low 7 support, above 7.50, potential to 8/8.50 ✅ $ONFO low 3 support, above 3.50, potential to 4/5 ✅ $MDXH .50 support, above .65, potential to .70/.80 ✅ $DARE 1.50 support, above 2, potential to 2.50/.70 ✅ Ideal long entry near current support 🎯 Ideal stop loss if below current support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
View on StockTwits ↗Updated gappers in after hours trading $AKAN $CAPR $ONFO $DARE $MDXH Enjoy your evening let's finish the week strong tomorrow!
View on StockTwits ↗💵Some Stocks to Watch for 14 Aug: ONFO AKAN MGRX BOXL MDXH $DARE $FGI $DFSC $CAPR 💪Below are results from today and this month's Top Alerts. 👉See Profile to Join Us.
View on StockTwits ↗$AKAN $CAPR $DARE $MDXH $ONFO watch akan crossing 52week highs next 🔥🔥🔥
View on StockTwits ↗Fun Friday Watchlist- Overnight Rippers $CAPR $AKAN $ONFO $DARE $MDXH
View on StockTwits ↗After Hours Top Gainers PT2 $MDXH $DARE $HTFL $ETON $TPCS
View on StockTwits ↗$DARE this might be one of those “why didn’t I take it” later
View on StockTwits ↗$DARE To be more specific. Between 5.50pm and 5.55pm ~829,000 shares were bought on avg for $2. That is $1,658,000. If a solo buyer, which the velocity of the price action suggests, I propose someone just took a 6.2% stake. Be on the look out for a SEC 13G or 13D filing. Long. GLTA
View on StockTwits ↗Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $MDXH $IMXI $DARE $HTFL !
View on StockTwits ↗Good evening, Gappers here in after hours trading here: $AKAN $CAPR $ONFO $MDXH $DARE I'll update later this evening.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2M | +178.4% | $-0.95 | $-1.34–$-0.56 | — | 2 |
| 2027 | $7M | +251.8% | $-0.48 | $-0.68–$-0.31 | — | 1 |
| 2028 | $35M | +369.0% | $0.02 | $0.01–$0.03 | 78.5× | 1 |
| 2029 | $102M | +194.1% | $1.41 | $0.91–$1.98 | 1.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.30 | $-0.20 | +32.6% |
| 2026-05-14 | $-0.33 | $-0.20 | +39.4% |
| 2026-03-26 | $-0.24 | $-0.02 | +91.7% |
| 2025-11-13 | $-0.33 | $-0.28 | +15.2% |
| 2025-08-14 | $-0.55 | $-0.45 | +18.2% |
| 2025-05-13 | $-0.63 | $-0.50 | +20.6% |
| 2025-03-31 | $-0.66 | $-0.64 | +3.0% |
| 2024-11-14 | $-0.60 |
| $-0.55 |
| +8.3% |
| $820295 |
| — |
| ATHAAthira Pharma, Inc. | $6.75 | -6.12% | $27M | — |
| CTXRCitius Pharmaceuticals, Inc. | $0.73 | -4.10% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry